REG - Ergomed plc - Board Appointment

ErgomedAnnouncement

20/08/2019 07:05

RNS Number : 5572J
Ergomed plc
20 August 2019
 


 
PRESS RELEASE
 
Board Appointment
 
 
Ian Johnson Appointed as Non-Executive Director
 
 
Guildford, UK - 20 August 2019: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, is pleased to announce that Ian Johnson will join the Board as a Non-Executive Director with immediate effect.
 
Ian has spent his business career in life sciences and has served on the boards of a number of public and private companies. He was founder and CEO of Biotrace International plc, a leading provider of rapid microbial testing systems. Biotrace was a listed company until its sale to 3M in December 2006. Ian was Non-Executive Chairman of Celsis Group Ltd from 2009 until 2015 and Chairman of Cyprotex plc, a CRO, which was acquired by Evotec AG in 2016. He was later Chairman of Quantum Pharma plc, which was acquired by Clinigen Group plc in 2017, and most recently Executive Chairman of Bioquell plc from 2016 until its acquisition by Ecolab Inc. in 2019.
 
Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: "We are pleased to welcome Ian to the Board. This appointment continues a series of measures we began more than a year ago to drive long term growth through a focus on our services business and to strengthen the Board and management team. Ian has spent his career in the life sciences industry and has a strong track record in building shareholder value. We look forward to his contributions as we continue towards our goal of building a leading independent global mid-tier CRO."
 
Ian Johnson said: "It is particularly exciting to be joining Ergomed's Board of Directors at the present time. Ergomed is a robust platform in the clinical services marketplace with its highly differentiated offering which combines specialist CRO services and pharmacovigilance. The Company has performed strongly in the recent period, is operating net cash positive and has no debt. I look forward to working with the Board as the Company continues to execute its planned strategy delivering on its clear potential for continued growth."
 
Save as disclosed below, in relation to current and prior directorships, Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Ian Johnson's appointment.
 
Mr Ian Roy Johnson, aged 66, has held the following directorships in the past five years:
 



Current Directorships


Klenitise Ltd




Directorships in the past five years


Development Bank of Wales PLC
MDH Defence Ltd
Quantum Pharma PLC  
Biofortuna Ltd    
Cyprotex PLC
Lumora Ltd    
Celsis Group Ltd   
Toximet Ltd        
Bioxyquell Ltd
Bioquell UK Ltd
Bioquell SAS
Bioquell Global Logistics (Ireland) Ltd
Bioquell Inc
Bioquell Defence Inc
Bioquell Professional Services Inc
Bioquell Asia Pacific Pte Ltd
Bioquell Technology (Shenzhen) Ltd
Bioquell Technology Canada Ltd
Bioquell PLC



 
Companies that went into administration and where creditors lost money as a result of liquidation:
 
Pure Options Solutions - Administrators appointed on 30 November 2010. The estimated deficiency to investors and creditors was £4.49 million.
 
Toximet Limited - Administrators appointed on 17 November 2015. The estimated deficiency to investors and creditors was £0.83 million.
 
 
ENDS
 
Enquiries:
 



Ergomed plc


 Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)








Richard Barfield (Chief Financial Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)








James Black (Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke







 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognised specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAGGUGCRUPBPGB